Drug-resistant tuberculosis bacteria may have figured out how to undermine the body’s ability to defend itself, according to a new study.
People who get sick with drug-resistant TB face daunting odds. Only about two in three survive the illness, unlike people with drug-sensitive TB, who have a more than 90 percent survival rate.
Part of the reason drug-resistant TB is so lethal is because some antibiotics of first choice don’t kill the TB bacteria, forcing doctors to treat the infection with second-line medications that are often more toxic and less effective.
Now, a new study with mice shows that the same mutation that makes TB bacteria withstand a first-line drug also elicits a different—and probably weaker—immune response.
“As the bacteria become drug resistant, they change physiologically and trick the immune system to behave differently,” says Shabaana A. Khader, associate professor of molecular microbiology and senior author of the paper, which appears in Nature Microbiology.
“If we’re going to fight TB bacteria effectively, we’re going to have to understand what the drug-resistant bacteria are doing to the immune system to elicit protection,” Khader says.
More lung damage
There have been hints for years that drug-resistant bacteria might interact with the body differently than drug-sensitive strains. Anecdotal reports suggest that resistant TB bacteria cause more damage to the lungs and spread more widely through the body.
For the study, researchers analyzed the immune response in mice infected with Mycobacterium tuberculosis, the bacteria that cause TB. They compared a strain that is resistant to all first- and many second-line antibiotics with a drug-sensitive strain of TB.
The mice’s immune systems battled the sensitive bacteria by releasing a powerful immune molecule known as IL-1 beta and ramping up the ability of their immune cells to burn sugar. Both actions are crucial for an effective immune assault on the TB bacteria.
But when the drug-resistant strain infected them, the mice failed to pull out the big guns. Their immune cells did not burn more sugar, and they failed to produce much IL-1 beta. Instead, they released a different immune molecule, IFN beta, which is associated with a feeble and sometimes detrimental immune response to TB.
“People always thought that development of drug resistance just meant that there’s a change in how bacteria respond to antibiotics,” Khader says. “But this shows that the whole immune environment is changing in ways that we haven’t been fully aware of.”
To find out why drug-resistant bacteria elicit a different immune response, the researchers scanned the whole genomes of several drug-resistant strains and found that a change of one letter in the genetic code gave bacteria the ability to withstand rifampicin, an important first-line antibiotic, and also altered the immune response.
Treating TB is a long, drawn-out process. The bacteria grow slowly and are wrapped in a protective shell, so it takes a combination of four antibiotics given repeatedly over six months to eradicate them.
Boosting the immune response would be like sending in fresh troops to a protracted battle—it could put an end to the fight, quickly and decisively. Clinical trials already are underway to find out whether immune-enhancing drugs combined with antibiotics improves outcomes for people with TB.
But because of the inherent dangers of working with drug-resistant bacteria, nearly all research into strengthening the immune response uses drug-sensitive strains.
“If you’re going to do host-directed therapeutics, we need to know what immune pathways to target,” Khader says. “And these pathways may turn out to be different for drug-sensitive and drug-resistant TB.”
The findings suggest that the people most in need of better therapeutics—those infected with drug-resistant strains—may not benefit from immune enhancers that are designed based on drug-sensitive bacteria.
“We don’t know enough about the differences between resistant and sensitive TB to be confident that the therapeutics and vaccines we’re designing are going to work,” Khader says. “We’re going to have to do those studies.”
The National Institutes of Health, the National Heart, Lung, and Blood Institute, the Ministry of Education and Science of the Russian Federation, and the medicine department at the University of Rochester funded the work.